SCHEMBL242420

SCHEMBL242420

CC1CCN(CCN)CC1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.57
CARM1 Q86X55 2/20 0.56
PRMT6 Q96LA8 2/20 0.56
PRMT1 Q99873 2/20 0.56
PRMT8 Q9NR22 2/20 0.56
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
ACHE P22303 3/20 0.47
HRH3 Q9Y5N1 2/20 0.47
PRMT3 O60678 1/20 0.44
GNAI3 P08754 1/20 0.42
GNAO1 P09471 1/20 0.42
GNAI1 P63096 1/20 0.42
SIGMAR1 Q99720 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7220231 0.98 ALOX15 (0.55) ALOX15CARM1PRMT6PRMT1PRMT8
SCHEMBL20366986 0.91 CARM1 (0.48) ALOX15CARM1PRMT6PRMT1PRMT8
SCHEMBL24951491 0.86
SCHEMBL14197772 0.86
SCHEMBL18781684 0.86
SCHEMBL1290862 0.86 CARM1 (0.52) CARM1PRMT6PRMT1PRMT8POLB
SCHEMBL25031743 0.84 SIGMAR1 (0.50) CARM1PRMT6PRMT1PRMT8POLB
SCHEMBL20234635 0.84 CARM1 (0.65) CARM1PRMT6PRMT1PRMT8POLB
SCHEMBL30786293 0.82 SIGMAR1 (0.53) CARM1PRMT6PRMT1PRMT8POLB
Trifluoroacetic Acid SCHEMBL4010460 0.82 POLB (0.49) ALOX15CARM1PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4457258-A1 POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM ARKEMA FRANCE (FR) 2024-11-06 EP claimed
CN-118488982-A Polyol catalyst for two-component polyurethane systems 阿科玛法国公司 2024-08-13 CN claimed
WO-2023126199-A1 POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM ARKEMA FRANCE (FR) 2023-07-06 WO claimed
EP-1633348-B1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARM INC (US) 2008-10-08 EP claimed
US-7432379-B2 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. (US) 2008-10-07 US claimed
EP-1633348-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP claimed
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-01-27 US claimed
WO-2004098589-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO claimed
EP-0765865-B1 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION SEIKAGAKU KOGYO CO LTD (JP) 2001-12-12 EP claimed
US-5763438-A ANTIVIRAL AGENTS SEIKAGAKU CORPORATION (JP) 1998-06-09 US claimed
EP-0765865-A1 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION SEIKAGAKU CORPORATION (JP) 1997-04-02 EP claimed
JP-63301297-A None JP disclosed
US-12528948-B2 Amino (meth)acrylates ALLNEX BELGIUM S.A. (BE) 2026-01-20 US disclosed
WO-2025053634-A1 NOVEL QUINAZOLINE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 고려대학교 산학협력단 2025-03-13 WO disclosed
EP-4457258-A1 POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM ARKEMA FRANCE (FR) 2024-11-06 EP disclosed
EP-0387381-A1 Process for producing unsaturated dicarboxylic acid imide compound MATSUSHITA ELECTRIC WORKS, LTD. (JP) 1990-09-19 EP disclosed
JP-S63301297-A METAL ROLLING OIL COMPOSITION DAIDO KAGAKU KOGYO KK 1988-12-08 JP disclosed
EP-0104506-B1 6-((CYCLIC AMINO)ALKYLAMINO)TETRAHYDROTRIAZOLO(3,4-A)PHTHALAZINES THE DOW CHEMICAL COMPANY (US) 1986-11-05 EP disclosed
US-4487930-A 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines THE DOW CHEMICAL COMPANY (US) 1984-12-11 US disclosed
EP-0104506-A1 6-((Cyclic amino)alkylamino)tetrahydrotriazolo(3,4-a)phthalazines THE DOW CHEMICAL COMPANY (US) 1984-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 ALOX15 1190/4885CARM1 4625/4885PRMT6 3826/4885
US-12528948-B2 Amino (meth)acrylates MAT2B, MAT1A, MMAB ALOX15 3780/4885CARM1 134/4885PRMT6 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.